MENU

Sponsored Seminar 8.4: Treating Schizophrenia in Criminal Justice Settings and the Consideration of a 2-month (1064 mg) Long-acting Injectable (LAI) Dosing Option Sponsored By: Alkermes

Sunday 1:00 PM - 2:00 PM

Room: 214

Schizophrenia is substantially overrepresented in the criminal justice system; the estimated prevalence of diagnosed schizophrenia is 2%-6.5% in state prison inmates and the prevalence is estimated to be less than 1% in the US adult population. Atypical long-acting injectable (LAI) therapies have recently been considered as a treatment option for medically appropriate individuals with schizophrenia as they transition from incarceration to community care settings. This program will review an LAI treatment option for people living with schizophrenia.

SPEAKERS

Patrick Hayes, MD, Medical Director, Imperial Calcasieu Human Services Authority, Lake Charles, LA